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Poster Session-II 149the two thenwe will giveOndansetron IV during chemotherapy only
(day 1 and 2) and prescribe oral Ondansetron 16mg daily for five days
as the oral formulation is more cost effective.
Method:Nausea assessment will be completed of twenty patients
who are undergoing auto out patient SCT for Myeloma with a con-
ditioning regimen of high doseMelphalan. Ten of those patients will
receive IV Ondansetron 16mg day 1 through day 7 and ten will re-
ceive IV Ondansetron 16mg day 1 and 2 then oral Ondansetron
16mg on days 3 through 7. Patients will be asked to keep a log of their
nausea daily using a nausea assessment scale. The following scale will
be used; 05 not at all, 15 a little bit, 25 somewhat, 35 quite a bit,
45 verymuch. This scale is currently being used in our SCT follow-
up clinic. Cost will be calculated with the help of our pharmacy staff.
Interpretation: Data will be analyzed and presented and anti-
emetic recommendations will be made based on these patient out-
comes and costs of two different regimens.421
PEDIATRIC BLOOD AND MARROW TRANSPLANTATION (BMT) MEDICA-
TION ERROR REPORTING SYSTEM (MERS): AN APPROACH TO IMPROV-
ING QUALITY OF CARE OF PEDIATRIC BMT RECIPIENTS
Shonfeld, T.1, Barrell, C.1, Lopez, I.2, Bhatia, M.3, Cairo, M.S.3,4,5
1 Morgan Stanley Children’s Hospital of New York Presbyterian, New
York, NY; 2 Morgan Stanley Children’s Hospital of New York Presbyte-
rian, New York, NY; 3 Columbia University, New York, NY; 4 Columbia
University, New York, NY; 5 Columbia University, New York, NY
MERS is an in house electronic system that facilitates all staff
members involved in patient care to anonymously report either an er-
ror or a near miss. Within the BMT program, the Quality Manage-
ment (QM) team usesMERS to improve the quality of care provided
to the pediatric BMT recipients. AnyMERS filed concerning pediat-
ric BMT patients are electronically sent to the Pediatric BMT QM
Nurse Coordinator daily. All events and near misses are distributed
to the chief of the Pediatric BMT Division, BMT Clinical Pharma-
cist, BMT CNS and BMT QM Medical Director. All events which
are considered as a sentinel event are acted on immediately. Monthly
meetings are held with the QM team to review all MERS reports.
Quarterly, all MERS reports are compiled and distributed into 6 cat-
egories including: Nursing, Pharmacy, Lab, Equipment, Falls and
Miscellaneous and are reviewed at our BMTQM Steering Commit-
tee Meetings. Performance improvement plans are developed based
on trends in the quarterly analysis. From September 2007–Septem-
ber 2008 90 MERS were reported concerning the pediatric BMT
population. The breakdown included: Nursing Error: 38%, Phar-
macy Error: 16%, Laboratory Error: 13%, Equipment Error 18%
Falls: 6% and Miscellaneous: 24%. Two performance improvement
initiatives were developed during this past year as a result of BMT
MERS reporting in the areas of Pharmacy and Equipment. MERS
filed by the BMTnursing staff was focused on anti - thymocyte glob-
ulin (ATG) and its location in themedication roomon the BMTunit.
Thismedication had no special label andwas not separated from sim-
ilar looking IV bags. Due to multiple MERS reported regarding the
danger of having the ATG bags within the same bin as the IVF bins,
a performance improvement plan was initiated including nursing and
pharmacy education and seperation of ATG bags from IVFs. Since
then, we have had no MERS reported on labeling or misadministra-
tion of ATG. Secondly, BMT nurses filedMERS on new IV connec-
tion caps that were causing splashes when the line was accessed,
difficulties in drawing blood, and increase CR-BSI. A performance
improvement plan resulted in change in caps and a subsequent reso-
lution of difficulties and reduction in CR-BSI. In summary, incident
reporting has a huge impact on the BMTQMprogram.These results
suggest that specific pediatric BMT incident reporting by an elec-
tronic system can result in change in practice and improvement in
quality of care to pediatric BMT recipients.422
SPIRITUALITY: THE ESSENTIAL SECRET
Burleson, J.K. Duke University Medical Center, Durham, NC
The subject of spirituality and it’s relation to health and specifi-
cally oncology, has risen to the forefront in nursing literature and re-search over the last decade. However, despite the increasing body of
literature on this topic, many healthcare providers feel ill prepared to
address a patient’s spiritual needs, and despite patients’ desire to dis-
cuss the topic, many providers ignore it altogether. A program was
developed for oncology healthcare providers with the purpose of re-
porting an integrative literature review, to increase participants un-
derstanding of spirituality as a concept with a broad definition to
encompass all patients. It also incorporated Parse’s nursing theory
of human becoming into this concept along with the key components
of spirituality, including a search for meaning, connectedness, and
survival of hope. These components were explored to purport the
importance of addressing spirituality with all patients, particularly
those in the oncology population, as existential questioning occurs
with a cancer diagnosis and patients struggle to find coping mecha-
nisms. The program also addressed the findings that the spirituality
of an oncology patient affects not only the patient, but the family as
a whole. The focus of patients and their caregivers may differ, thus
causing conflicts within a family. Ways to acknowledge these strug-
gles and interventions were discussed, providing a knowledge base
for providers. It is also important for the provider to understand
that to support a patient during a time of spiritual need or to address
spirituality as a piece of holistic care, the provider must first under-
stand his/her own spirituality. The audience participated in a short
spiritual exercise to direct them in exploring their own spiritual facet.
Spiritual assessment tools have improved over the last decade and are
available for clinical use. These were discussed and assessed as well.
Finally, interventions for patients in spiritual distress were discussed
in the form of an original acronym, REST. The findings of this lit-
erature review and program development will be presented as sec-
tions addressing the definitions of spirituality with the key
components found as commonalities throughout all definitions,
the importance of addressing spirituality, the affect of spiritual dis-
tress on the family, available assessment tools and their validity and
reliability, and interventions for spiritual distress, in the form of
REST, an original acronym.423
THE PRIMARY MYELOMA NURSE: AN EXPANDED ROLE OF THE TRANS-
PLANT COORDINATOR
Daily, K., Thirlwell, S. Moffitt Cancer Center, Tampa, FL
Traditionally, the role of the transplant coordinator in the care of
multiple myeloma (MM) patients is focused on coordination of
transplant screening, stem cell mobilization and collection, high
dose chemotherapy, stem cell rescue and post-transplant recovery.
The Moffitt Myeloma Program recognizes MM as a chronic disease
and provides comprehensive care over the entire continuum from di-
agnosis to end of life. Rather than ‘‘hopping from lily pad to lily pad’’
of care providers (from primary physician, to hematologist, to trans-
plant specialist then returning to hematologist), the patient experi-
ences unfragmented transitions in care through remissions and
exacerbations of MM. Within this novel model of care delivery,
the transplant coordinator has an expanded role as PrimaryMyeloma
Nurse (PMN). The role of the PMNmay be compared to that of pri-
mary nurses in the care of other chronic diseases such as chronic
heart failure and chronic obstructive pulmonary disease. A patient
is referred by their primary physician and will remain with the Mof-
fitt Myeloma Team for diagnosis, induction, possible transplant, re-
lapse treatment, clinical trials and end of life care. The PMN is ‘‘the
tie that binds’’, essential to linking all aspects of care and assisting im-
plementation of all phases of this trajectory. Beyond transplantation,
the PMN acquires knowledge and expertise of chemotherapy, novel
and experimental agents for induction and relapse treatment of MM.
The PMN establishes a stable therapeutic relationship and develops
a personalized plan of care for patients and families according to
their unique needs during each phase of MM. She ensures smooth
delivery of care in multiple locations including outpatient clinics,
outpatient infusion centers, inpatient units and the patient’s home.
At this time, the benefit of the novel role of PMN over that of tradi-
tional coordinator has not been examined. Our goal is to offer an al-
ternative approach to caring for MM as it has evolved into a chronic
disease. In the future, we hope that like a primary nurse of other
chronic diseases, a primary nurse for MM is recognized as beneficial
to patients and families.
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A MULTIDISCIPLINARY INITIATIVE TO REDUCE VANCOMYCIN-RESIS-
TANT ENTEROCOCCUS (VRE) INCIDENCE ON A PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT UNIT
Gainer, L.1, Johnson, B.1, Nickley, J.1, Potter-Bynoe, G.2, Scanlon, P.2,
Lehmann, L.3 1 Children’s Hospital Boston, Boston, MA; 2 Children’s Hos-
pital Boston, Boston, MA; 3 Dana-Farber Cancer Institute, Boston, MA
Hematopoetic stem cell transplant (HSCT) patients are at risk for
bacteremia caused by resistant organisms, such as vancomycin-resis-
tant enterococcus (VRE), due to repeated courses of antimicrobial
therapy and neutropenia. Early VRE bacteremia during HSCT has
been associatedwith highmorbidity andmortality. Thus, implemen-
tation and monitoring of recommended infection prevention mea-
sures is critical. Recommendations include: judicious use of
antibiotics, health care worker education, hand hygiene compliance,
Standard and Contact precautions adherence, and surveillance for
VRE, which in our unit includes active surveillance cultures (ASC).
In the spring of 2008, an increase in VRE incidence prompted the
formation of amultidisciplinary team comprised ofHSCT, Infection
Control, and Environmental Services (ESD) personnel. Microbiol-
ogy records for our 13-bed pediatric HSCTunit revealed that the in-
cidence of VRE had increased from 1.8/1000 patient days in 2007 to
3.8/1000 patient days during the first 6 months of 2008. Our inves-
tigation revealed gaps in our ASC protocol. Admission ASC was of-
ten overlooked, making it difficult to determine whether the VRE
was acquired on our unit. To improve case finding, we emphasized
collecting ASC on admission with Infection Control performing
random audits to assess compliance. Our hospital protocol for dis-
continuing Contact precautions for patients with VRE is based on
serial rescreening. However, our investigation revealed that the pro-
tocol may not be applicable in HSCT patients prior to engraftment.
Therefore, HSCT patients with VRE must now be at least 100 days
post transplant before evaluation to discontinue Contact precautions
can be initiated. To address the potential role of the environment in
VRE transmission, we reviewed existing daily and discharge proce-
dures and enhanced the cleaning procedures of all patient rooms
and common areas. In lieu of restricting the use of common areas
by families, education on the importance of hand hygiene when en-
tering and leaving their child’s room was emphasized. As an added
measure, our unit requires HSCT patients to remain in their rooms
for the first 7 days of their admission to the unit. The use of preemp-
tive Contact precautions pending ASC results has been implemented
as an additional prevention strategy. During the 3rd quarter of 2008,
VRE incidence decreased to 1.9/1000 patient days and improvement
in compliance with our ASC protocol was realized.425
LOW-DOSE AZACITIDINE (AZA) AS MAINTENENCE THERAPY AFTER
ALLOGENEIC HEMATOPOIETIC STEM TRANSPLANTATION (HSCT) IN
RELAPSED AML OR MDS: A NURSING PERSPECTIVE
Metoyer, L.J., Champlin, R., Gulbis, A., da Silva, L., de Lima, M.,
Giralt, S. University of Texas at MD Anderson Cancer Center, Houston,
TX
Supportive care for allogeneic HSCT in patients with AML or
MDShas improved significantly over timewhich has resulted in a de-
crease in the rate of non relapse mortality. However, the incidence of
relapse has not been greatly impacted. Disease status at the time of
transplant is the most valid predictor for relapse, and recurrence re-
mains a major cause of treatment failure in this patient population.
Modification of treatment preparative regimens has not proven to
be beneficial. Despite the investigation of multiple chemotherapy/
radiation therapy combinations, reduction in the risk of relapse with-
out an increase of non relapsemortality has not been achieved for pa-
tients transplanted with relapsed and or refractory disease.
Azacitidine (AZA) is approved by the FDA for the treatment of
MDS at doses that are unlikely to be tolerated post HSCT due to
mylesuppression. In patients with relapsed AML or MDS at the
time of transplant, maintenance therapy with low dose AZA after
HSCT may provide adjuvant support for the allogeneic graft versus
leukemia affect, potentially decreasing recurrence rates. There is
limited experience with administration of chemotherapy and/or
the use of AZA in this setting. A dose and schedule finding study
for the use of AZA as maintenance therapy is being performed atMDAndersonCancer Center. AZA is given for four cycles in a doses
ranging from 8–32 mg/m2 starting on day1 42 subcutaneously daily
for 5 days every 28 days for a total of 4 cycles. Conditioning regimen
included gemtuzumab ozogamicin 2 mg/m2, fludarabine 120 mg/m2,
and melphalan140 mg/m2. Graft versus host disease (GVHD)
prophylaxis was tacrolimus/mini-methotraxate, with rabbit anti-
thymocyte globulin (rATG) in unrelated donor HSCT. Criteria for
patients to receive AZA include complete remission on day1 30 after
transplant with donor chimerism, no grade III/IV GVHD, platelets
greater than 10,000 and ANC. 500/ mm3. In all, 88 cycles were de-
livered at 8 (n5 7), 16 (n5 5), 24 (n5 21) and 32mg/m2 (n5 9). AZA
possible associated toxicities include grade I/II or III thrombocytope-
nia, grade I nausea, grade II fatigue, grade III transaminase elevation,
conjunctival erythema, prurititus, confusion, retinal hemorrhage,
grade II creatinine elevation, oral ulcers, papilledema and pulmonary
hemorrhage, and infections. Nursing issues related to drug adminis-
tration and monitoring will be discussed in further detail.426
PROPHYLACTIC CIPROFLOXACIN IN BK VIRUS POSITIVE ALLOGENEIC
STEM CELL TRANSPLANT RECIPIENTS AT KOSAIR CHILDREN’S HOSPITAL
Hente, M.L.1, Grant, J.O.1, Bowman, T.1, Wilkerson, R.1, Waldron, R.1,
Cheerva, A.C.2 1 Kosair Children’’s Hosptial, Louisville, KY; 2 University
of Louisville, Louisville, KY
Polyoma BK virus (BKV) is associated with hemorrhagic cystitis
(HC) in allogenenic stem cell transplants. This virus was first re-
ported in 1971, but testing for it has been available only for approx-
imately the past 5 years. It is very prevalent in human subjects (up to
80% of adults are infected), but only causes clinical issues in immu-
nocompromised patients possibly leading to hepatitis, retinitis,
pneumonitis and encephalopathy. Recent reports have suggested
that Ciprofloxacin (Cipro) can decrease urinary BKV reactivation af-
ter HSCT. Therefore, this institution began utilizing prophylactic
Cipro to attempt to reduce viral load and therefore, also the inci-
dence of HC. In this institution, Cipro was given prophylactically
to 4 BKV positive patients, of whom, 3 diagnoses were acute myeloid
leukemia and 1 diagnosis was acute lymphocytic leukemia. Two pa-
tients had BKV detected by PCR in their urine and no symptoms of
HC and 2 who were positive had moderate to severe clinical symp-
toms of HC. Standard preparative regimes were utilized with diverse
donor graft sources. All patients started with intravenous dosing of
Cipro, 1 with high dose due to severe HC and 3 with prophylaxis
dose. They were all switched to oral dosing when tolerated. All pa-
tients tolerated Cipro well and there were no side effects due to
this medication. Quantitative BKV PCR’s were done on urine at
least weekly and on serum if the patient became febrile. Urinalyses
were done frequently throughout the treatment period. Only 1 pa-
tient had positive serumPCR’s, whichwere noted prior to institution
of Cipro. The PCR continued to rise even with institution of Cipro
and never became negative. This patient succumbed to multiple in-
fections and GVHD (1145) after being on Cipro for 7 weeks. The
other patients (150, 1124 and1153) remain alive, 2 free of clinical
symptoms and off Cipro (given 17-50 and 130–50), and 1 remains
in the hospital on Cipro (150) and negative for clinical symptoms.
After initiation of Cipro, the BKV urinary viral loads decreased in
2 patients and increased in 2 patients. Two patients had HC before
starting Cipro (1 continued to increase viral load while the other de-
creased) and 2 did not have HC (1 continued to increase viral load
while the other did not). In conclusion, 50% of the patients in our
institution remained symptom free and a larger study should be
done to determine if Cipro is effective in decreasing BK urinary viral
loads and HC in stem cell transplant patients.427
A MULTIDISCIPLINARY CLINICAL PROCESS TO ADDRESS THE STEM CELL
TRANSPLANTATATION PATIENT WITH SPECIAL NEEDS
Tomczak, N., Davis, L., Neumann, J., Johnston, P., Sorenson, S. MD
Anderson Cancer Center, Houston, TX
Background: Undergoing a Stem Cell Transplantation (SCT)
can be a very complex process for patients, their caregivers, and
healthcare workers. When additional factors are included: a history
